Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.

Abstract

Four patients with Parkinson's disease, optimally treated with levodopa/carbidopa (LD/CD) tablets but experiencing severe motor fluctuations, underwent an open trial of a levodopa/carbidopa/ascorbic acid solution (LCAS) orally at timed intervals. LCAS reduced bradykinesia, decreased dysfunctional dyskinesia, and increased functional "on" time when compared with previous LD/CD tablet therapy. Oral LCAS allowed better titration of levodopa dosage and offered a more predictable response than LD/CD tablets. Preparation and oral consumption of LCAS was easy and inexpensive. LCAS may be a practical alternative for patients whose motor fluctuations fail to respond to optimal therapy with LD/CD tablets.

Statistics

050100'97'99'01'03'05'07'09'11'13'15'17
Citations per Year

123 Citations

Semantic Scholar estimates that this publication has 123 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Kurth1993OralLS, title={Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.}, author={Martin Kurth and James W Tetrud and Ian Irwin and William H. Lyness and James Langston}, journal={Neurology}, year={1993}, volume={43 5}, pages={1036-9} }